ChromaDex Corp announced a partnerhisp with MyPharma2Go to conduct cross-border sales of Tru Niagen and Tru Niagen Pro in Brazil. Nicotinamide riboside (NR), the active ingredient in Tru Niagen, is a precursor to nicotinamide adenine dinucleotide (NAD+), an endogenous compound that is linked with cellular function and metabolism.
 
MyPharma2Go is an American company focused on Brazil and Latin America that allows patients to have direct access to international medicines and supplements, and monitors the international shipping process from origin to delivery.
 
The cross-border distribution strategy allows for 300 mg 30 count bottles, 300 mg 90 count bottles, and 300 mg 30 count stick packs of Tru Niagen to be purchased by consumers. Additionally, MyPharma2Go is working with Brazilian health care professionals to distribute Tru Niagen Pro bottles, which feature 500 mg of Niagen, the highest single-capsule dose available.
 
“In the last five years, our cross-border business has impacted more than 30,000 health professionals and has served more than 240,000 patients throughout Brazil,” said André Di Donato, CEO and founder of MyPharma2Go. “Through our partnership with ChromaDex and Tru Niagen, we will ensure our premium service delivers the best global products to our customers in Brazil.”
 
Niagen has been the subject of 20 published and peer-reviewed clinical studies, many of which involve daily doses of 1,000 mg or more of Niagen. The ingredient has achieved regulatory acceptance for use in supplements by the U.S. FDA and the European Commission. It has been approved by Therapeutic Goods Administration in Australia for use in complementary medicines, for use in medical foods by the Food Standards Australia New Zealand, and as a natural health product by Health Canada.